J. Meier

Endocrinology, Diabetes and Metabolism · Molecular Metabolism · 2008–2020

A researcher in the Science corpus: 4 papers; trusts 4 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

Whom J. Meier trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. J. Drucker
  2. M. Nauck
  3. John B. Buse
  4. Jens J. Holst
  5. Ralph DeFronzo

Who trusts J. Meier overall

  1. M. Nauck
  2. L. Knudsen
  3. M. Cerf

Papers from J. Meier's perspective

Ordered by how strongly the researchers J. Meier trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. (The Lancet)
  2. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection (Nature Medicine)
  3. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. (Diabetes)
  4. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. (New England Journal of Medicine)
  5. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. (Journal of Clinical Investigation)
  6. Inhibition of gastric inhibitory polypeptide signaling prevents obesity (Nature Medicine)
  7. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction (Journal of the American Medical Association (JAMA))
  8. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. (The Lancet Diabetes and Endocrinology)
  9. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. (The Lancet Diabetes and Endocrinology)
  10. The biology of incretin hormones. (Cell Metabolism)

Their papers